Johnson & Johnson (JNJ) Tops Q4 EPS by 1c, Beats on Revenue; Reaffirms FY24 Growth Targets

Johnson & Johnson (NYSE: JNJ) reported Q4 EPS of $2.29, $0.01 better than the analyst estimate of $2.28. Revenue for the quarter came in at $21.4 billion versus the consensus estimate of $21 billion.

The company re-confirms guidance for 2024 with operational sales growth of 5.0% - 6.0% and adjusted operational EPS of $10.55 - $10.75, reflecting growth of 7.4% at the mid-point. The current analyst estimate is EPS of $10.67.

For earnings history and earnings-related data on Johnson & Johnson (JNJ) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• BMO Capital Resumes Global Net Lease (GNL), Upgrades to Outperform
• Phillip Securities Reiterates Buy Rating on Sea Ltd. (SE)